share_log

Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study

Benzinga ·  Dec 19 19:43

OCU410 (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment